Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
about
Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirinValue of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceDirect-acting antivirals for chronic hepatitis C.Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesWhy We Should Be Willing to Pay for Hepatitis C Treatment.Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the NetherlandsEstimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report.The cost-effectiveness of boceprevir for hepatitis C.Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature.Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss.Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.The cost-effectiveness of treating triple coinfection with HIV, tuberculosis and hepatitis C virus.Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Ribavirin induced anaemia: the effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat.Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.Direct-acting antivirals for chronic hepatitis C
P2860
Q26784321-C2D26D7B-B4FC-4E3C-A4AF-82F79F246239Q28072257-AC500769-2BBB-4A34-A39A-6DA1D98956B8Q34557595-3257BBBB-3395-4982-A91E-DBD49FA16FECQ35563500-0071F7EB-82D4-4DFC-AB40-5127792196A4Q35619161-C58D0211-11C7-4AC3-A9D8-69337BBA6805Q36075161-7CC01DFF-551B-4D44-A632-E0567ED53911Q36155257-65EB0C98-0DB1-4E9A-8B28-07691B63CE0BQ36336005-BFF9A08E-86F8-43DF-BE07-D1FD86EF4D02Q37286544-2C3EB6D8-1624-455F-81D9-B7E6C47A3488Q37715878-ED9561E0-E9E8-4E95-9BC5-9655E9934E76Q38202682-1C8A5DB2-24AE-4CF3-82DB-ABFA38B0042BQ38206573-5ADA4CD3-3813-4D0C-AF1A-43C23579807EQ38691333-CD97D70C-A217-4576-ACEC-5C2EB015E1CCQ38720758-C52CFF67-58F9-4453-996A-2ACF5F5683D7Q39102936-01F6A646-1371-4304-9CD1-216004F56160Q39137372-AD78AFA7-9CDC-4D35-ABCA-C768B0000C4AQ39910149-33765223-EFC7-40D4-80A0-633455D2D49AQ40291907-CAC83E6D-F195-4F27-B1ED-E84094299284Q40302226-FD4624EC-40FF-40F3-A00E-4374126CC482Q40711194-E9914F96-93A7-473D-B977-CDDF181A208AQ42048758-6D9AB992-FE94-4349-9542-276DE99637ACQ42965148-0EC5F308-B763-410B-AA06-69AC353EB6FAQ52653977-35F5C933-0440-49A0-A311-5A793C9EC53AQ55280669-EF08A76A-55F3-4CE4-87D9-0573BB029847Q57389418-58ACDCF4-FC87-430B-A2CB-A1126E7BE6FE
P2860
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Boceprevir for previously untr ...... t-effectiveness modeling study
@ast
Boceprevir for previously untr ...... t-effectiveness modeling study
@en
Boceprevir for previously untr ...... t-effectiveness modeling study
@nl
type
label
Boceprevir for previously untr ...... t-effectiveness modeling study
@ast
Boceprevir for previously untr ...... t-effectiveness modeling study
@en
Boceprevir for previously untr ...... t-effectiveness modeling study
@nl
prefLabel
Boceprevir for previously untr ...... t-effectiveness modeling study
@ast
Boceprevir for previously untr ...... t-effectiveness modeling study
@en
Boceprevir for previously untr ...... t-effectiveness modeling study
@nl
P2093
P2860
P356
P1476
Boceprevir for previously untr ...... t-effectiveness modeling study
@en
P2093
Antoine C El Khoury
Clifford A Brass
Elamin H Elbasha
Jagpreet Chhatwal
Jean-Pierre Bronowicki
Shannon Allen Ferrante
P2860
P2888
P356
10.1186/1471-2334-13-190
P50
P577
2013-04-27T00:00:00Z
P5875
P6179
1035708417